Ann Hematol (2015) 94:911–918 DOI 10.1007/s00277-015-2330-2
ORIGINAL ARTICLE
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia Juan-Carlos Hernández-Boluda & Eduardo Arellano-Rodrigo & Francisco Cervantes & Alberto Alvarez-Larrán & Montse Gómez & Pere Barba & María-Isabel Mata & José-Ramón González-Porras & Francisca Ferrer-Marín & Valentín García-Gutiérrez & Elena Magro & Melania Moreno & Ana Kerguelen & Manuel Pérez-Encinas & Natàlia Estrada & Rosa Ayala & Carles Besses & Arturo Pereira & on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Received: 27 January 2015 / Accepted: 1 February 2015 / Published online: 14 February 2015 # Springer-Verlag Berlin Heidelberg 2015
Abstract It is unclear whether anticoagulation guidelines intended for the general population are applicable to patients with polycythemia vera (PV) and essential thrombocythemia (ET). In the present study, the risk of thrombotic recurrence was analyzed in 150 patients with PV and ET treated with vitamin K antagonists (VKA) because of an arterial or venous thrombosis. After an observation period of 963 patient-years, the incidence of re-thrombosis was 4.5 and 12 per 100 patientyears under VKA therapy and after stopping it, respectively J.
ORIGINAL ARTICLE
Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia Juan-Carlos Hernández-Boluda & Eduardo Arellano-Rodrigo & Francisco Cervantes & Alberto Alvarez-Larrán & Montse Gómez & Pere Barba & María-Isabel Mata & José-Ramón González-Porras & Francisca Ferrer-Marín & Valentín García-Gutiérrez & Elena Magro & Melania Moreno & Ana Kerguelen & Manuel Pérez-Encinas & Natàlia Estrada & Rosa Ayala & Carles Besses & Arturo Pereira & on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)
Received: 27 January 2015 / Accepted: 1 February 2015 / Published online: 14 February 2015 # Springer-Verlag Berlin Heidelberg 2015
Abstract It is unclear whether anticoagulation guidelines intended for the general population are applicable to patients with polycythemia vera (PV) and essential thrombocythemia (ET). In the present study, the risk of thrombotic recurrence was analyzed in 150 patients with PV and ET treated with vitamin K antagonists (VKA) because of an arterial or venous thrombosis. After an observation period of 963 patient-years, the incidence of re-thrombosis was 4.5 and 12 per 100 patientyears under VKA therapy and after stopping it, respectively J.
